Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Aptevo Therapeutics FY 2023 GAAP EPS $(1.420) Beats $(1.720) Estimate

Author: Benzinga Newsdesk | March 05, 2024 09:14am
Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(1.420) per share which beat the analyst consensus estimate of $(1.720) by 17.44 percent.

Posted In: APVO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist